Valsartan
- Generic Name
- Valsartan
- Brand Names
- Dafiro, Diovan, Diovan Hct, Entresto, Exforge, Exforge Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N5O3
- CAS Number
- 137862-53-4
- Unique Ingredient Identifier
- 80M03YXJ7I
- Background
Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, olmesartan, and irbesartan. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and syn...
- Indication
Valsartan is indicated for the treatment of hypertension to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It is also indicated for the treatment of heart failure (NYHA class II-IV) and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensin-converting ...
- Associated Conditions
- Cardiovascular Mortality, Diabetic Nephropathy, Heart Failure, Hypertension, Moderate Essential Hypertension, Chronic heart failure with reduced ejection fraction (NYHA Class II), Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Hospitalization due to cardiac failure
- Associated Therapies
- -
Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2009-02-09
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT00839683
- Locations
- 🇺🇸
Mds Pharma Services (Us) Inc., Neptune, New Jersey, United States
Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2009-01-13
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 144
- Registration Number
- NCT00821574
Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise
- Conditions
- Interventions
- First Posted Date
- 2009-01-09
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 68
- Registration Number
- NCT00819767
- Locations
- 🇬🇧
Investigative Site, Leicester, United Kingdom
8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2011-05-02
- Lead Sponsor
- Novartis
- Target Recruit Count
- 451
- Registration Number
- NCT00809926
- Locations
- 🇺🇸
Sites in USA, East Hanover, New Jersey, United States
Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study)
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2010-06-03
- Lead Sponsor
- Kagoshima University
- Target Recruit Count
- 250
- Registration Number
- NCT00790946
- Locations
- 🇯🇵
Chuwa Tei,MD,FACC,FAHA, Kagoshima, Japan
Regression of Fatty Heart by Valsartan Therapy
- Conditions
- Interventions
- First Posted Date
- 2008-09-03
- Last Posted Date
- 2019-01-17
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Registration Number
- NCT00745953
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168)
- Conditions
- Interventions
- First Posted Date
- 2008-08-21
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Fundación Lindavista del Corazón AC
- Target Recruit Count
- 12
- Registration Number
- NCT00738972
Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics?
- First Posted Date
- 2008-08-12
- Last Posted Date
- 2008-08-12
- Lead Sponsor
- Assaf-Harofeh Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT00732966
Study of Inflammation and Oxidative Stress in Persons Undergoing Dialysis
- Conditions
- Interventions
- First Posted Date
- 2008-08-11
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 19
- Registration Number
- NCT00732069
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Renal Protective Effects of Renin Angiotensin System (RAS) Inhibitor in Peritoneal Dialysis Patients
- Conditions
- Interventions
- First Posted Date
- 2008-07-24
- Last Posted Date
- 2015-05-20
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 200
- Registration Number
- NCT00721773
- Locations
- 🇨🇳
The 1st Affiliated Hospital, Sun Yet-sen University, GuangZhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.